(Total Views: 435)
Posted On: 09/05/2019 6:14:47 PM
Post# of 154915
https://seekingalpha.com/instablog/498952-bre...n-thursday
CytoDyn (OTCQB:CYDY) is maintained as a Buy with a $1.50 price target (the stock currently sells for 40 cents a share) this morning at H.C. Wainwright. Here is an explanation around their valuation methodology on this $150M market cap company.
Our 12-month price target is derived from an estimated market value of the firm at $585M. It includes a discounted cash flow-based asset value of $592M for leronlimab in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $8M debt. Assuming 391M shares outstanding at the end of May 2020, this translates to a per share value of approximately $1.50.”
CytoDyn (OTCQB:CYDY) is maintained as a Buy with a $1.50 price target (the stock currently sells for 40 cents a share) this morning at H.C. Wainwright. Here is an explanation around their valuation methodology on this $150M market cap company.
Our 12-month price target is derived from an estimated market value of the firm at $585M. It includes a discounted cash flow-based asset value of $592M for leronlimab in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $8M debt. Assuming 391M shares outstanding at the end of May 2020, this translates to a per share value of approximately $1.50.”
(1)
(0)
